Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000713109 | SCV000843680 | uncertain significance | not provided | 2017-10-31 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000713109 | SCV002019135 | likely pathogenic | not provided | 2019-09-06 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002532949 | SCV003442458 | likely pathogenic | Familial hyperkalemic periodic paralysis | 2022-04-11 | criteria provided, single submitter | clinical testing | Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. This sequence change replaces arginine, which is basic and polar, with leucine, which is neutral and non-polar, at codon 1448 of the SCN4A protein (p.Arg1448Leu). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with clinical features of paramyotonia congenita (PMID: 18166706; Invitae). ClinVar contains an entry for this variant (Variation ID: 586518). This variant disrupts the p.Arg1448 amino acid residue in SCN4A. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 1316765, 7809121, 8005599, 16801039). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |